跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,821 条关于
“GI-aGVHD”
全部
1,821
临床试验
1,327
药物
97
机构
10
资讯
387
9个月前
Microbiota Therapy MaaT013 Achieves 62% Response Rate in Refractory GI-aGVHD Phase 3 Trial
去年
MaaT013 Shows Promise in Phase 3 Trial for GI-aGvHD
去年
MaaT Pharma's MaaT013 Shows Promising Long-Term Efficacy in Refractory GI-aGvHD
去年
MaaT Pharma Completes Enrollment in Phase 3 Trial of MaaT013 for Acute Graft-versus-Host Disease
2年前
MaaT Pharma Advances Microbiome Therapeutics in Oncology
5个月前
MaaT Pharma's Microbiome Therapy Shows 62% Response Rate in Severe Graft-versus-Host Disease
3天前
MaaT Pharma's Xervyteg Hits Negative CHMP Trend Vote in Re-Examination for aGvHD Approval
去年
ReAlta Life Sciences Receives European Orphan Drug Designation for Graft-versus-Host Disease Treatment
去年
Microbiome Therapeutics Pipeline Expands with 180+ Novel Therapies in Development Across 140 Companies
2个月前
GvHD Pipeline 2026: Cell-Based, Microbiome and Targeted Therapies Reshape Treatment Landscape
第 1 页,共 39 页
上一页
下一页